Helixgate

Helixgate

Uncategorized

STAT+: Pump the brakes on AI, buddy; and deposition deadlock

This is the online version of STAT’s weekly email newsletter Health Care Inc. Sign up here.

Hey! Are you going to be in Washington, D.C. on May 19? I’ll be moderating a Georgetown University panel discussion on vertical integration in health care. Jonathan Kanter, the former top antitrust official at the Department of Justice, also will make remarks. It’s gonna be lit. Reserve a spot here. And as always, a penny for your thoughts: bob.herman@statnews.com.

The Elevance exec you need to know

Lawsuits alleging health insurers defrauded Medicare and other government programs take forever to litigate. Maybe they’re more about the friends you make along the way.

Continue to STAT+ to read the full story…

Read More

Published

on

This is the online version of STAT’s weekly email newsletter Health Care Inc. Sign up here.

Hey! Are you going to be in Washington, D.C. on May 19? I’ll be moderating a Georgetown University panel discussion on vertical integration in health care. Jonathan Kanter, the former top antitrust official at the Department of Justice, also will make remarks. It’s gonna be lit. Reserve a spot here. And as always, a penny for your thoughts: bob.herman@statnews.com.

The Elevance exec you need to know

Lawsuits alleging health insurers defrauded Medicare and other government programs take forever to litigate. Maybe they’re more about the friends you make along the way.

Continue to STAT+ to read the full story…

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

FDA search for new CBER head focused on small group of final candidates

Published

on

The FDA has narrowed its search for a new leader of its Center for Biologics Evaluation and Research to three to four final candidates, according to a person familiar with the matter.

The agency hopes …

Continue Reading

Uncategorized

Celcuity strengthens case for ASCO-spotlighted breast cancer drug

The new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year’s biggest meeting for cancer research.

Read More

Published

on

The new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year’s biggest meeting for cancer research.

Read More

Continue Reading

Uncategorized

Passage cuts 75% of workforce after FDA trial design request

Published

on

Passage Bio, which has been working toward a registrational trial for a drug candidate whose indications include frontotemporal dementia, is exploring strategic alternatives in addition to cutting staff.

Continue Reading
Advertisement

Trending